NASDAQ:CNST - Constellation Pharmaceuticals Stock Price, News & Analysis

$6.68
-0.87 (-11.52 %)
(As of 08/23/2019 04:00 PM ET)
Today's Range
$6.47
Now: $6.68
$7.76
50-Day Range
$7.10
MA: $9.05
$10.17
52-Week Range
$4.01
Now: $6.68
$14.04
Volume31,066 shs
Average Volume27,494 shs
Market Capitalization$172.48 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CNST
CUSIP21036U206
Phone617-714-0555

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.60 per share

Profitability

Net Income$-59,920,000.00

Miscellaneous

Employees82
Market Cap$172.48 million
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable

Receive CNST News and Ratings via Email

Sign-up to receive the latest news and ratings for CNST and its competitors with MarketBeat's FREE daily newsletter.


Constellation Pharmaceuticals (NASDAQ:CNST) Frequently Asked Questions

What is Constellation Pharmaceuticals' stock symbol?

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

How were Constellation Pharmaceuticals' earnings last quarter?

Constellation Pharmaceuticals Inc (NASDAQ:CNST) released its earnings results on Wednesday, August, 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.80). View Constellation Pharmaceuticals' Earnings History.

When is Constellation Pharmaceuticals' next earnings date?

Constellation Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Constellation Pharmaceuticals.

What price target have analysts set for CNST?

3 equities research analysts have issued 1 year price objectives for Constellation Pharmaceuticals' stock. Their predictions range from $17.00 to $18.00. On average, they expect Constellation Pharmaceuticals' stock price to reach $17.6667 in the next year. This suggests a possible upside of 164.5% from the stock's current price. View Analyst Price Targets for Constellation Pharmaceuticals.

What is the consensus analysts' recommendation for Constellation Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Constellation Pharmaceuticals.

Has Constellation Pharmaceuticals been receiving favorable news coverage?

Media headlines about CNST stock have been trending positive recently, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Constellation Pharmaceuticals earned a news impact score of 2.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the near future. View News Stories for Constellation Pharmaceuticals.

Who are some of Constellation Pharmaceuticals' key competitors?

What other stocks do shareholders of Constellation Pharmaceuticals own?

Who are Constellation Pharmaceuticals' key executives?

Constellation Pharmaceuticals' management team includes the folowing people:
  • Mr. Jigar Raythatha, Pres, CEO & Director
  • Ms. Emma Reeve, Sr. VP, CFO Treasurer & Sec. (Age 58)
  • Dr. Adrian M. Senderowicz, Sr. VP & Chief Medical Officer (Age 55)
  • Dr. Danny Reinberg Ph.D., Co-Founder
  • Dr. Yang Shi Ph.D., Co-Founder

When did Constellation Pharmaceuticals IPO?

(CNST) raised $80 million in an IPO on Thursday, July 19th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

Who are Constellation Pharmaceuticals' major shareholders?

Constellation Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.18%), Vanguard Group Inc. (2.05%), Northern Trust Corp (0.57%), P.A.W. Capital Corp (0.46%), Alps Advisors Inc. (0.21%) and Bank of New York Mellon Corp (0.14%). Company insiders that own Constellation Pharmaceuticals stock include Alexandria Venture Investments, Anthony B Evnin and James E Flynn. View Institutional Ownership Trends for Constellation Pharmaceuticals.

Which institutional investors are selling Constellation Pharmaceuticals stock?

CNST stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp. View Insider Buying and Selling for Constellation Pharmaceuticals.

Which institutional investors are buying Constellation Pharmaceuticals stock?

CNST stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., P.A.W. Capital Corp, BlackRock Inc., Alps Advisors Inc., Jacobs Levy Equity Management Inc., Northern Trust Corp, Acadian Asset Management LLC and Wells Fargo & Company MN. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Alexandria Venture Investments, Anthony B Evnin and James E Flynn. View Insider Buying and Selling for Constellation Pharmaceuticals.

How do I buy shares of Constellation Pharmaceuticals?

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Constellation Pharmaceuticals' stock price today?

One share of CNST stock can currently be purchased for approximately $6.68.

How big of a company is Constellation Pharmaceuticals?

Constellation Pharmaceuticals has a market capitalization of $172.48 million. The company earns $-59,920,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Constellation Pharmaceuticals employs 82 workers across the globe.View Additional Information About Constellation Pharmaceuticals.

What is Constellation Pharmaceuticals' official website?

The official website for Constellation Pharmaceuticals is http://www.constellationpharma.com/.

How can I contact Constellation Pharmaceuticals?

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]


MarketBeat Community Rating for Constellation Pharmaceuticals (NASDAQ CNST)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  61 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  133
MarketBeat's community ratings are surveys of what our community members think about Constellation Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel